JP2009544734A - 目の障害の予防および処置のための内皮分化遺伝子ファミリー３（ｅｄｇ−３、ｓ１ｐ３）レセプターのアンタゴニスト - Google Patents

目の障害の予防および処置のための内皮分化遺伝子ファミリー３（ｅｄｇ−３、ｓ１ｐ３）レセプターのアンタゴニスト Download PDF

Info

Publication number
JP2009544734A
JP2009544734A JP2009521989A JP2009521989A JP2009544734A JP 2009544734 A JP2009544734 A JP 2009544734A JP 2009521989 A JP2009521989 A JP 2009521989A JP 2009521989 A JP2009521989 A JP 2009521989A JP 2009544734 A JP2009544734 A JP 2009544734A
Authority
JP
Japan
Prior art keywords
antagonist
alkyl
receptor
eye
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009521989A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544734A5 (https=
Inventor
デブラ エル． フレーノア，
アラン アール． シェパード，
イオク−ホウ パン，
Original Assignee
アルコン リサーチ， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルコン リサーチ， リミテッド filed Critical アルコン リサーチ， リミテッド
Publication of JP2009544734A publication Critical patent/JP2009544734A/ja
Publication of JP2009544734A5 publication Critical patent/JP2009544734A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2009521989A 2006-07-25 2007-07-25 目の障害の予防および処置のための内皮分化遺伝子ファミリー３（ｅｄｇ−３、ｓ１ｐ３）レセプターのアンタゴニスト Pending JP2009544734A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83308006P 2006-07-25 2006-07-25
PCT/US2007/074351 WO2008014338A2 (en) 2006-07-25 2007-07-25 Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders

Publications (2)

Publication Number Publication Date
JP2009544734A true JP2009544734A (ja) 2009-12-17
JP2009544734A5 JP2009544734A5 (https=) 2011-03-10

Family

ID=38982306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521989A Pending JP2009544734A (ja) 2006-07-25 2007-07-25 目の障害の予防および処置のための内皮分化遺伝子ファミリー３（ｅｄｇ−３、ｓ１ｐ３）レセプターのアンタゴニスト

Country Status (11)

Country Link
US (2) US20080025973A1 (https=)
EP (1) EP2068856A2 (https=)
JP (1) JP2009544734A (https=)
KR (1) KR20090033886A (https=)
CN (1) CN101505744A (https=)
AU (1) AU2007279311A1 (https=)
BR (1) BRPI0714593A2 (https=)
CA (1) CA2657480A1 (https=)
MX (1) MX2009000907A (https=)
WO (1) WO2008014338A2 (https=)
ZA (1) ZA200900316B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781617B2 (en) 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
EP1806338B1 (en) 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof
PL1932522T3 (pl) * 2005-10-07 2012-09-28 Kyorin Seiyaku Kk Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
CA2659598A1 (en) * 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Amino phosphate derivative and s1p receptor modulator having same as an active ingredient
JP5140593B2 (ja) * 2006-08-08 2013-02-06 杏林製薬株式会社 アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
WO2009117335A2 (en) * 2008-03-17 2009-09-24 Allergan, Inc. S1p3 receptor inhibitors for treating inflammation
US20120071448A1 (en) * 2009-05-05 2012-03-22 Allergan, Inc. S1P3 Receptor Inhibitors for Treating Conditions of the Eye
US20110039900A1 (en) * 2009-08-11 2011-02-17 Allergan, Inc. Isothiozoles for treating conditions of the eye
JP2013505967A (ja) * 2009-09-30 2013-02-21 スティーフェル リサーチ オーストラリア ピーティーワイ リミテッド 美容用フォーム
CN102146411B (zh) * 2011-01-06 2013-01-02 中国人民解放军第三军医大学第三附属医院 新型双功能抗瘢痕和组织纤维化寡聚核苷酸药物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019779A1 (en) * 1994-01-21 1995-07-27 Yale University Deltex proteins, nucleic acids, and antibodies, and related methods and compositions
JP2002332278A (ja) * 2001-05-08 2002-11-22 Human Science Shinko Zaidan Ｅｄｇ受容体拮抗作用を有する複素環誘導体
JP2005247691A (ja) * 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013811A1 (de) * 1993-11-17 1995-05-26 Byk Nederland Bv Verwendung substituierter thiazolidinderivate zur behandlung von erhöhtem augeninnendruck
US5545626A (en) * 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
EP1253929B1 (en) * 2000-02-09 2007-05-23 BAS Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
JP2001261575A (ja) * 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
US7351407B2 (en) * 2002-04-30 2008-04-01 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
US7241790B2 (en) * 2002-07-30 2007-07-10 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
CA2495917A1 (en) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
FR2845003A1 (fr) * 2002-09-30 2004-04-02 Merck Sante Sas Utilisation de derives de thiazolidinedione comme inhibiteurs de l'aldose reductase
WO2005009962A1 (en) * 2003-07-15 2005-02-03 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
WO2006063033A2 (en) * 2004-12-06 2006-06-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
US8546452B2 (en) * 2005-10-12 2013-10-01 Toa Eiyo Ltd. S1P3 receptor antagonist
CN101460458A (zh) * 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019779A1 (en) * 1994-01-21 1995-07-27 Yale University Deltex proteins, nucleic acids, and antibodies, and related methods and compositions
JP2002332278A (ja) * 2001-05-08 2002-11-22 Human Science Shinko Zaidan Ｅｄｇ受容体拮抗作用を有する複素環誘導体
JP2005247691A (ja) * 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬

Also Published As

Publication number Publication date
AU2007279311A1 (en) 2008-01-31
WO2008014338A3 (en) 2008-12-24
US20080025973A1 (en) 2008-01-31
KR20090033886A (ko) 2009-04-06
US20100183629A1 (en) 2010-07-22
ZA200900316B (en) 2010-05-26
CA2657480A1 (en) 2008-01-31
CN101505744A (zh) 2009-08-12
EP2068856A2 (en) 2009-06-17
BRPI0714593A2 (pt) 2013-05-07
MX2009000907A (es) 2009-02-04
WO2008014338A2 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
JP2009544734A (ja) 目の障害の予防および処置のための内皮分化遺伝子ファミリー３（ｅｄｇ−３、ｓ１ｐ３）レセプターのアンタゴニスト
EP2262476B1 (en) Drug delivery to the anterior and posterior segments of the eye using eye drops.
JP4934653B2 (ja) Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
US20120115870A1 (en) Control of intraocular pressure using alk5 modulation agents
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
RU2370267C2 (ru) Антагонисты cdk2 в качестве антагонистов короткой формы фактора транскрипции c-maf для лечения глаукомы
JP2009298808A (ja) Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
US20040213782A1 (en) Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure
JP4482726B2 (ja) Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
EP3747471A1 (en) Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
TW201927298A (zh) 賽佩普斯特（Ｓｅｐｅｔａｐｒｏｓｔ）及Ｒｈｏ激酶抑制劑之組合醫藥
US20100247548A1 (en) Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders
US20110105574A1 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
WO2022034909A1 (ja) セペタプロストを含有する医薬製剤
WO2014138018A1 (en) Preservative free bimatoprost and timolol solutions
Mokbel et al. Rho-Kinase Inhibitors as a novel medication for Glaucoma Treatment–A Review of the literature
JP7580123B2 (ja) 血管新生関連疾患の予防又は治療用医薬組成物
US20210363247A1 (en) Novel Treatments of Glaucoma
TWI917317B (zh) 細胞外基質調節劑
WO2004047868A1 (ja) Limキナーゼ阻害作用を有する化合物を有効成分とする緑内障治療剤
JP7429500B2 (ja) 角膜上皮障害治療剤
KR20080111092A (ko) 고안압증 조절 및 녹내장의 치료를 위한 프레닐트랜스퍼라아제 억제제
Virani et al. An Update on Pharmacotherapy of Glaucoma
HK40091616A (zh) 用於治疗干性年龄相关性黄斑变性、地图状萎缩和青光眼相关性神经变性的no-pde5抑制剂
WO2020166679A1 (ja) 眼圧下降用医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120723

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120830

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121129